Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fund Letter | Ariel Investments, LLCAriel International Fund | PharmaceuticalsPharmaceuticals | Ariel International Fund - MRK.DE We bought Merck KGaA, a leading life science tools company, based on our conviction that a biopharma spending recovery is underway following a prolonged period of inventory destocking and funding constraints. The inflection is... | NEUTRAL | View Pitch → | |
| Sep 2, 2026 | Fund Letter | Ariel Investments, LLCAriel Global Fund | PharmaceuticalsPharmaceuticals | Ariel Global Fund - MRK.DE We purchased Merck KGaA, a leading life science tools company, based on our conviction that a biopharma spending recovery is underway following a prolonged period of inventory destocking and funding constraints. The inflection is... | NEUTRAL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Oldfield Partners Overstone Global Large Cap | PharmaceuticalsPharmaceuticals | Long MRK.DE (Merck) Merck was a new purchase during the quarter. Merck started as... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.